Quest Diagnostics 2013 Annual Report Download - page 14

Download and view the complete annual report

Please find page 14 of the 2013 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 131

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131

10
• Prescription Drug Monitoring and Toxicology.
- We added several new tests, including testing for synthetic cannabinoids, synthetic stimulants, zolpidem and
other prescription drugs.
- We expanded our genetic testing services that assist physicians in their treatment of patients with chronic
pain.
Diagnostic Solutions
Clinical Trials Testing.
We are a leading provider of central laboratory testing performed in connection with clinical research trials on new
drugs, vaccines and certain medical devices. Clinical research trials are required by the FDA and non-U.S. regulatory
authorities to assess the safety and efficacy of new drugs, vaccines and some medical devices. We see opportunities to develop
pharmacogenetic and pharmacogenomic tests to help speed drug approval processes for our clinical trials customers and,
capitalizing on the trend to personalized medicine, to better focus patient therapy based on a patient's genetic markers. We have
biomarker capabilities that advance our efforts to develop these tests, and offer an “end-to-end” array of services for companion
diagnostics.
We have clinical trials testing centers in the United States, the United Kingdom and India, and we provide clinical
trials testing in Argentina, Brazil, China and Singapore through affiliated laboratories. We serve a broad range of large
pharmaceutical, biotechnology and medical device companies.
Life Insurer Services.
We are the largest provider of risk assessment services to the life insurance industry in North America. We also
provide risk assessment services for insurance companies doing business outside North America. We charge our life insurance
customers on a fee-for-service basis, typically under multi-year agreements.
Our risk assessment services comprise underwriting support services to the life insurance industry, including data
gathering, paramedical examinations and clinical laboratory testing. The laboratory tests that we perform and data we gather
are designed to assist insurance companies objectively to evaluate the mortality risks of applicants. Factors such as the number
of applications for life insurance policies and the level of underwriting services sought affect the level of services we provide to
our customers. Most of our specimen collections and paramedical examinations are performed by our network of
approximately 5,500 paramedical examiners at the applicant's home or workplace. We also offer paramedical examinations
through approximately 600 of our patient service centers, and operate approximately 80 locations other than patient service
centers in North America where we provide paramedical examinations, bringing the total number of sites in North America
where we can provide these examinations to approximately 680. We also contract with third parties to coordinate providing
these exams at more than 350 additional locations globally.
Diagnostic Products.
Focus Diagnostics and Celera develop and manufacture products that enable healthcare professionals to make
healthcare diagnoses, including products for testing for the professional market. We offer these products in the United States
and, through distributors, in other countries.
Focus Diagnostics develops, manufactures and markets diagnostic products which can be performed on a variety of
instrument platforms. Focus Diagnostics' product lines include Simplexa® molecular chemistries with a focus on infectious
disease and hospital-acquired infections, HerpeSelect® HSV serology, and a line of DxSelectTM IFA and ELISA products for
testing for emerging infectious diseases. Focus Diagnostics maintains an exclusive global distribution agreement with 3M
Corporation to bring real-time polymerase chain reaction products to the market using Simplexa® molecular chemistries and
the 3MTM Integrated Cycler, a compact bench-top instrument. Focus Diagnostics strives to be the first company to provide
diagnostic solutions for emerging infectious diseases. Its past accomplishments include assays for West Nile Virus, SARS and
Influenza A H1N1. Focus Diagnostics sells its diagnostic products to large academic medical centers, hospitals and
commercial laboratories.
Celera offers a number of market-leading high complexity molecular diagnostic products in segments such as HIV-1
drug resistance testing (under the ViroSeq® brand), reproductive genetics and transplantation (under the AtriaTM and
AlleleSeqr® brands). Celera products are sold to a broad spectrum of customers.